Pelage Pharma Gains New Injection of Funds to Progress into Phase 2
Pelage Pharma Presents Data From its Phase 1 Clinical Study: Update (03/09/2024)
On March 9th, Pelage Pharma unveiled data at the AAD 2024 Annual Meeting, showcasing PP405. Through translational and Phase 1 clinical studies, PP405 demonstrated its ability to reactivate dormant hair follicle stem cells, triggering hair regrowth.
Pelage Pharma has provided an overview of their presentation in a press release.
In both ex vivo studies on human facelift skin and Phase 1 clinical trials, PP405 exhibited significant potential. Topical applications of 0.006% and 0.06% PP405 onto human facelift skin led to increased lactate dehydrogenase (LDH) activity in hair follicle stem cells within 24 hours, accompanied by increased cell proliferation in the bulge of the hair follicle—where hair follicle stem cells reside.
The presentation also revealed some more information from the Phase 1 trial, which concluded in January 2024. Participants were treated with 0.05% topical PP405, and after 7 days, there was a statistically significant increase in cell proliferation (as measured by Ki-67) compared to the baseline. Furthermore, new hair germs were observed during this time, indicating a change from the telogen phase to anagen. The formulation also received positive reviews from participants.
Pelage Pharma will begin its Phase 2a trial in mid-2024 and will recruit both men and women with androgenetic alopecia.
Original Article
Positive news for Pelage Pharma as they close their Series A funding round.
Pelage Pharma is a regenerative medicine company developing a topical treatment called PP405 that is claimed to reactivate dormant hair follicle stem cells and trigger new hair growth. This treatment is aimed at people suffering from all types of hair loss. Pelage has raised $16.75 million, which will help the company progress to Phase 2 clinical trials following the completion of its first-in-human Phase 1 clinical trial. Google Ventures (GV) led the funding round with participation from Main Street Advisors, Visionary Ventures, and YK Bioventures.
PP405
During the initial clinical evaluation of PP405, Pelage’s indication for androgenetic alopecia and other hair loss conditions, it was observed that applying 0.05% of the product topically for seven days caused no adverse effects. This trial confirmed that the product was suitable for daily use. Additionally, this trial demonstrated that the product worked as expected by increasing a key marker for stem cell activation, which was in line with the anticipated mechanism of action identified in pre-clinical studies. These findings are scheduled for presentation at the upcoming American Academy of Dermatology meeting, which takes place on March 8-12 in San Diego, California.
We can expect Phase 2 trials to begin in mid-2024.
Reflections
Follicle Thought has covered Pelage Pharma news here and here. It is promising to see the advancements made by Pelage, and we look forward to seeing the results of the Phase 1 trial when they are presented at the AAD Annual Meeting. Several other companies also target or utilize stem cells in hair loss treatments. These include dNovo Bio, who work on stem cell regeneration (you can read about them here), Niostem, and Stemson Therapeutics.
Let us know what you think about this news in the comments.
Posted in Hair Growth Treatment
When will there be a new topical or other product out that people can try? Still seeing a lot of early stage products on here which are great. But it would be nice to see some things that will be released within a month or two or even 6 months? We’ve been hopeful about 2023 and 2024 products for a long time, but nothing seems to be getting released? Can someone please comment on what may be coming out in the very near future?
Couldn’t agree more Brian!
Don’t forget about niostem!
Absolutely! Will add them in!
What are the odds the Niostem developers are not collecting Electroencephalography (EEG) data of their users through their headset device and their mobile app, and hair fall prevention was just a marketing strategy to increase their user base? I am saying this because they are claiming exceptionally good results with their device without providing much evidence.
I have seen an EEG headset, and it looks exactly the same as their device. EEG data can be used for many purposes like understanding brain-computer interface, Neuroscience and Psychology research, Neuromarketing. For example, this data can also be used to predict the password of a user’s account whenever he/she types it while wearing the device.
Many companies are also willing to buy EEG data for huge amounts for improve their marketing campaigns by better understanding their customer.
Niostem look legit as team and innovation and even transparency but then they start giving the 6x better than fin and minox and share 3 months improvement pics that doesn’t really show that much of an improvement which makes me question them. Nevertheless mine should arrive end of April so lets see
Is there another thread for products which will be released soon? Know you provided an update on near term products last year?
There are mixed reviews on niostem Does it work? Has FT reviewed this product?
Their webinar today contained some interesting new info – https://niostem.webinargeek.com/webinar/replay/eT1ah9Ka5Fw3hCEDprqRyAN09hHC7AOi__PzHKdOM7U/
https://newatlas.com/science/keratin-gel-hairloss/
Hopefully some newd
Hey FT,
I got a long-ish question about this. Mind if I send in the “Contact” section? I assume that you’re a busy man and don’t want to waste too much of your time.
Either way your work here’s appreciated.
Yep, feel free to send it over!
It seems like there’s a disagreement about if stem cells are dormant or if they disappear completely. Is this true? Should we be able to see that somehow?
In many MtF trans people taking female hormones to transition, you see an impressive revival of “dead” hair follicles. This gives me hope that these follicles aren’t actually dead just very dormant.
Hello admin!
Is there any news about PP405? Thanks in advance 😀